Pharmaceutical Treatments for Typical CKD Comorbidities
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 1699
Special Issue Editors
2. Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
Interests: nutrition in chronic kidney disease; hemodialysis; natural active compounds for prevention of chronic non-communicable diseases; body composition assessment; uremic sarcopenia; oxidative stress; microbiome in CKD; endothelial dysfunction in CKD
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chronic kidney disease (CKD) is characterized by numerous metabolic disorders and comorbidities that increase the risk of its progression toward end-stage renal disease (ESRD) and the mortality risk, worsening the patient's quality of life. These comorbidities include diabetes mellitus, arterial hypertension, protein energy wasting, mineral bone disorders, metabolic acidosis, hyperhomocysteinemia, uremic sarcopenia, uremic gastropathy, normochromic and normocytic anemia, electrolyte imbalance, dyslipidemia and gut dysbiosis. In this context, the identification and use of new pharmacological treatments are of particular relevance for the clinical management of CKD patients.
The purpose of our Special Issue is to take stock of the most innovative pharmacological and non-pharmacological therapies that employ a holistic approach to treating CKD patients.
Prof. Annalisa Noce
Dr. Manuela Di Lauro
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- natural bioactive compounds
- adjuvant treatment
- protein energy wasting
- mineral bone disorders
- metabolic acidosis
- hyperhomocysteinemia
- uremic sarcopenia
- PLADO diet
- anemia in CKD
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.